莫西沙星和哌拉西林他唑巴坦/阿奇霉素在治疗社区获得性肺炎中的最小成本分析

Minimum Cost Analysis of Moxifloxacin and Piperacillin Tazobactam Combined with Azithromycin Therapy for Community-Acquire Pneumonia

目的选取莫西沙星(A)与哌拉西林钠他唑巴坦钠/阿奇霉素(B)两组治疗方案,研究治疗社区获得性肺炎(CAP)的临床效果和成本。方法采用回顾性方法,对鹤壁市人民医院2019年1月至2020年12月住院的CAP患者的病历资料研究,筛选出两种治疗方案的病例,并进行治疗效果、最小成本分析。结果两组的临床有效率分别为88.9%和84.2%,不良反应发生率分别为2.22%和2.63%,两组比较均无统计学差异(P>0.05);采用最小成本分析进行经济学评价,A组的治疗总成本5992.5元,B组的治疗总成本为6227.8元,A组成本低于B组。结论两组治疗CAP的疗效相似,莫西沙星的经济学优势明显。

Objective To explore the clinical efficacy and cost of moxifloxacin(A)and Piperacillin tazobactam combined with azithromycin(B)in the treat of Community-Acquire Pneumonia(CAP).Methods For retrospective survey methodology,83 CAP patients were selected from January 2019 to December 2020 in Hebi People's Hospital.The patients were divided into group A and group B.According to their treatment,namely group A with moxifloxacin and group B with piperacilin tazobactam combined with azithromycin.The clinical fficacy and minimum cost of two groups were compared.Results Total response rates of group A and B were 89%and 84.2%;the incidence of ADR were 2.22 and 2.63%,without statistical significance(P>0.05).Minimum cost analysis was adopted for economic evaluation;treatment cost of group A was 5992 yuan,and that of group B was 6222 yuan.Conclusion The two group of drugs have a similar effective for CAP,and the advantage of moxifloxacin is obvious.